+33 3 74 02 03 03

Category Archives: Corporate

Starkage Therapeutics appoints Benjamin Le Calvé as CSO

– Dr. Le Calvé will lead the research activities of StarkAge Therapeutics and manage key collaborations with academic and industrial partners
– He joins from Celyad Oncology where he was Senior Scientist Early Development Group
– He brings expertise in senescence and a wealth of highly relevant international experience from academia and biopharmaceutical industry


Lille, France, Mai 10, 2022
– StarkAge Therapeutics (SATX), a pioneering discovery-stage biotechnology company focusing on cellular senescence-related diseases, announces the appointment of Dr. Benjamin Le Calvé as Chief Scientific Officer, reporting to Dr. Pierre-Michel Bringer, CEO. Dr. Le Calvé will sit on the Management Committee1 and will chair StarkAge Therapeutics Scientific Advisory Board2.

I am delighted to welcome Benjamin Le Calvé to StarkAge Therapeutics” said Dr. Pierre-Michel Bringer, “Benjamin’s personal academic background and professional experience, including in the field of senescence, will be instrumental in driving StarkAge Therapeutics to the next level of development.” In his tenure as Senior Scientist of the Early Development Group at Celyad Oncology, Benjamin lead the development of an shRNA platform for the allogeneic CAR-T products through the identification of new potential targets increasing the persistence and activity of cell therapy.

As CSO, Dr. Le Calvé will refine the current discovery strategy and implement it. He will supervise the Lille-based research team and all key discovery project and scientific operations. In addition he will oversee and supervise StarkAgeTx’s growing international IP portfolio. Collaborations with academic and industrial partners are an important part of the SATX strategy, and he will manage all existing partnerships and actively seek to establish new opportunities.

We have made significant progress in the past months, and I express my gratitude to Dr. Frédérik Oger for the phenomenal work he accomplished as acting CSO” added Dr. Thierry Mathieu, President and Founder of StarkAge Therapeutics.“He has been instrumental in crystalizing our Research Strategy and furthering important collaborations which will provide access to multi-omics3 capabilities. Frédérik will accompany us through our upcoming seed round and will continue to play a key role in our collaboration with EGID4.

Dr. Le Calvé holds a Ph.D. in Pharmaceutical and Biomedical Sciences from the Free University of Brussels, Belgium and an MS in Engineering for Health and Drugs, option Biotechnology and Management from the University of Joseph Fourier in Grenoble, France. He has 27 scientific publications to his name in peer-reviewed journals. Benjamin lives in Bierges, Belgium with his wife and two children.

 

About senescence

Cellular senescence is a stress-induced, durable cell-cycle arrest of previously replication-competent cells. Senescent cells can be beneficial as well as detrimental regarding host physiology and disease. Indeed, while cellular senescence can facilitate physiological processes such as tissue repair and wound healing, the actions of their secreted pro-inflammatory cytokines can promote tissue dysfunctions, especially during aging. In this context, the rate at which senescent cells accumulate within tissues increases with aging leading to age-related disorders causing diseases such as idiopathic pulmonary fibrosis5,6 (IPF) and many others7,8,9,10. Consequently, these detrimental senescent cells are considered a potential therapeutic target in age-related disorders. Nevertheless, the challenge remains to specifically target detrimental senescent cells while avoiding altering the functions of beneficial ones.

 

About StarkAge Therapeutics

StarkAge Therapeutics (SATX) is a pioneering privately held discovery-stage biotechnology company based in Lille, France. It was founded in 2018 by Dr. Thierry Mathieu based on the idea that eliminating disease-specific senescent cells using immunotherapy could deliver significant therapeutic benefits to patients.
Its ambition is to delay or halt disease progression and improve the quality of life of patients with age-related diseases.

Increasing evidence in literature confirms senescent cell accumulation as a hallmark in various aged-related diseases such as idiopathic pulmonary fibrosis5,6, neurodegenerative diseases7, metabolic dysfunction8,9 or hepatic steatosis10. Recent scientific reviews11,12 identified potential targets and set the foundations for testing applications in humans.

StarkAge Therapeutics’ unique expertise originates from its proprietary biomarker discovery platform, ExoCiseTM, which enables the characterization of senescent cell biomarkers from patient-derived extracellular vesicles and their specific validation for each disease.

StarkAge Therapeutics has selected Idiopathic Pulmonary Fibrosis (IPF) as its lead program. Other fibrotic diseases or metabolic diseases such as NAFLD / NASH are under evaluation.

 

Contacts

StarkAge Therapeutics
Institut Pasteur Lille – 1 Rue du Professeur Calmette – 59800 Lille – Tel:  +33 3 74 02 03 03

Dr. Pierre-Michel Bringer, CEO
pierre-michel.bringer@StarkAgeTX.com

 

References

  1. Management Committee = Comité de Direction (CoDir)
  2. https://starkagetx.com/starkage-therapeutics-establishes-its-scientific-advisor-board-of-international-independent-experts-sab-meets-for-the-first-timecientific-advisory-board-and-holds-their-foundational-meeting/
  3. OMICs https://en.wikipedia.org/wiki/Multiomicshttps://en.wikipedia.org/wiki/Omics
  4. EGID https://egid.fr/en/egid-european-genomic-institutes-for-diabetes/
  5. Hernandez-Gonzalez F et al., Cellular Senescence in Lung Fibrosis. Int J Mol Sci. 2021 Jun 29;22(13):7012.
  6. Kellogg DL et al., Cellular Senescence in Idiopathic Pulmonary Fibrosis. Curr Mol Biol Rep. 2021 Aug 12:1-10
  7. Baker DJ et al., Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest. 2018 Apr 2;128(4):1208-1216.
  8. Palmer AK et al.,Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. 2019;18(3):e12950.
  9. Aguayo-Mazzucato C et al., Acceleration of beta Cell Aging Determines Diabetes and Senolysis Improves Disease Outcomes. Cell Metab. 2019.
  10. Ogrodnik M et al., Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017;8:15691.
  11. Di Micco, R., Krizhanovsky, V., Baker, D. et al. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol 22, 75–95 (2021).
    https://www.nature.com/articles/s41580-020-00314-w
  12. Rossi, M.; Abdelmohsen, K. The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets. Cells 2021, 10, 1740.
    https://www.mdpi.com/2073-4409/10/7/1740

StarkAge Therapeutics establishes its Scientific Advisor Board of international independent experts and holds their foundational meeting

–  This Board advises company executives and guides the scientific team
–  It comprises leading international independent experts
–  Kick-off meeting held earlier this month in Paris


Lille, France, Febuary 12, 2022
– StarkAge Therapeutics (SATX), a pioneering discovery-stage biotechnology company focusing on cellular senescence-related diseases, announced today it has established its Scientific Advisory Board (SAB) comprised of leading international independent experts.

The main purpose of StarkAge Therapeutics SAB is to:

  • Advise the company President and executive team concerning current and future R&D strategy and opportunities
  • Guide the Chief Scientific Officer (CSO) and scientific team on key next steps and tools
  • Review and discuss science innovation and technology trends relevant to StarkAge Therapeutics R&D operations

“The expertise of these international experts is invaluable for our young start-up,” said Dr. Pierre-Michel Bringer CEO of StarkAge Therapeutics. “We are very thankful for their time and strategic advice and delighted that they have joined us”.

The Scientific Advisory Board includes the following external personalities:

    • David Bernard, PhD: Dr. David Bernard is a cell and molecular biologist by training with strong expertise in cellular senescence. Currently heading up the Cellular Senescence, Cancer and Aging team at The Cancer Research Center of Lyon (CRCL), Dr. Bernard’s team is developing several research projects focused on new mechanisms and actors of cellular senescence they have identified in regulating cancer, age-related alterations, for example, fibrosis and inflammation, and aging.
    • Vincent Cottin, MD: Dr. Vincent Cottin is Professor of Respiratory Medicine and coordinator of the National Reference Centre for Rare Pulmonary Diseases at the Louis Pradel Hospital and the Claude Bernard University in Lyon. For many years, this center has pioneered clinical care and research for patients with rare and orphan lung diseases. It has recently been recognized as the only center in France to be part of the European Reference Center network for interstitial lung disease (ERN-Lung, ILD). Prof. Cottin’s research interests include rare ‘orphan’ pulmonary diseases, including lymphangioleiomyomatosis, idiopathic interstitial pneumoniae and especially idiopathic pulmonary fibrosis.
      He is a member of the Scientific Advisory Board of the European Pulmonary Fibrosis Federation and Section Editor for interstitial lung disease for European Respiratory Journal.
    • Fabrizio D’Adda di Fagagna, PhD: Dr. Fabrizio d’Adda di Fagagna is a cell and molecular biologist at IFOM in Milan and CNR in Pavia (Italy) who studies the involvement of the DNA damage response (DDR) pathways in physiologically relevant processes such as aging and cancer. Dr. D’Adda di Fagagna discovered the engagement of DDR factors in the maintenance of telomeres and demonstrated that cellular senescence, a form of cell aging, is the outcome of DDR activation caused by the direct recognition of critically short or damaged telomeres.
    • Ana O’Loghlen, PhD: Dr. Ana O’Loghlen is an expert in cellular senescence in a variety of contexts such as aging, cancer, and age-related diseases. The focus of her Epigenetics & Cellular Senescence lab at the Blizard Institute of the Queen Mary University of London is understanding the basic mechanisms regulating cellular senescence and its influence on the microenvironment, and the understanding and identification of new components of the Senescence Associated Secretory Phenotype (SASP) and investigating their role with the microenvironment in the context of aging and cancer.
    • Pascal Pfister, MD: Dr. Pfister is an expert in drug development, whose career spans 3 decades with Novartis Pharmaceuticals in France, Switzerland, and the US, in a range of therapeutic fields including the areas of inflammatory, respiratory and cardiometabolic disease where he contributed to the development of many new therapeutic solutions. His most recent contribution was leading the clinical approval of the siRNA inclisiran. Earlier in his career, Dr. Pfister was CSO of Nicox, a French-listed biotechnology company.

“We are privileged to have the opportunity to work with these exceptional thought leaders” added Dr. Frédérik Oger CSO of StarkAge Therapeutics . “We are testing IPF, our lead program, with our cellular senescence biomarker platform ExoCiseTM, If successfully completed, it could lead to helping the fight against many other age-related diseases, including in metabolic disorders.”

She full SAB gathered for the first time earlier this month in Paris in a hybrid format. During this kick-off meeting, SATX R&D Strategy was presented and discussed, benefiting from multiple inputs and suggestions for consideration, and thus refined.“The rich discussions we had opened new avenues of thinking that could prove immensely useful to StarkAge Therapeutics” added Dr. Bringer. The SAB will meet 4 times a year.

StarkAge Therapeutics recently announced been awarded1 2€ million in non-dilutive funding, the maximum allowed per project in Bpifrance Deeptech program.
see our press release here.

A further capital increase will likely be required to fully fund their pre-clinical IPF program before engaging with US and European regulatory agencies.

About senescence

Cellular senescence is a stress-induced, durable cell-cycle arrest of previously replication-competent cells. Senescent cells can be beneficial as well as detrimental regarding host physiology and disease. Indeed, while cellular senescence can facilitate physiological processes such as tissue repair and wound healing, the actions of their secreted pro-inflammatory cytokines can promote tissue dysfunctions, especially during aging. In this context, the rate at which senescent cells accumulate within tissues increases with aging leading to age-related disorders causing diseases such as idiopathic pulmonary fibrosis2,3 (IPF) and many others4,5,6,7. Consequently, these detrimental senescent cells are considered a potential therapeutic target in age-related disorders. Nevertheless, the challenge remains to specifically target detrimental senescent cells while avoiding altering the functions of beneficial ones.

About ExoCiseTM

ExoCise is StarkAge Therapeutics’ proprietary platform designed to analyze extracellular vesicles (EVs), particularly exosomes and microvesicles, identifying robust and specific biomarkers for senescent cells in disease-setting by their specific multi-OMICs8 characterization.

EVs are secreted by virtually all cell types in the body and released in body fluids, particularly blood. EVs contain various molecules such as RNA, proteins, enzymes, cytokines etc.  Some of these molecules are specific to the tissue they originate from, and even specific to certain cells within that tissue (biomarkers). EVs secreted from diseased or senescent cells to the blood could be used to detect and diagnose such conditions with a simple blood draw.

By applying ExoCise to patients with age-related diseases involving senescent cell accumulation, StarkAge Therapeutics expects to design safe and targeted immunotherapy solutions, setting StarkAge Therapeutics apart from competitors’ approaches with senolytic drugs which lacked safety and selectivity.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a severe and debilitating disease with limited-or-no therapeutic options, in which the lungs become fibrotic and scarred9. It is a progressive illness where breathing becomes increasingly difficult over time until patients die from IPF.  There is currently no treatment that can stop the evolution of the disease, or even reverse the scarring of the lungs.

IPF prevalence10 is estimated between 14 and 27.9 cases per 100,000 habitants in the US, in Europe 1.25 to 23.4 cases per 100,000 habitants in Europe.

The estimated mean life expectancy11, for IPF patients is 2-5 years from the time of diagnosis. Estimated mortality rates are 64.3 deaths per million in men and 58.4 deaths per million in women. .

About StarkAge Therapeutics

StarkAge Therapeutics (SATX) is a pioneering privately held discovery-stage biotechnology company based in Lille, France. It was founded in 2018 by Dr. Thierry Mathieu, with scientific support from Dr. Müge Ogrunc, based on the idea that eliminating disease-specific senescent cells using immunotherapy could deliver significant therapeutic benefits to patients.

Its ambition is to delay or halt disease progression and improve the quality of life of patients with age-related diseases.

Increasing evidence in literature confirms senescent cell accumulation as a hallmark in various aged-related diseases such as idiopathic pulmonary fibrosis2,3, neurodegenerative diseases4, metabolic dysfunction5,6 or hepatic steatosis7. Recent scientific reviews12,13 identified potential targets and set the foundations for testing applications in human.

StarkAge Therapeutics unique expertise originates from its proprietary biomarker discovery platform, ExoCiseTM, which enables the characterization of senescent cell biomarkers from patient derived extracellular vesicles and their specific validation for each disease.

StarkAge Therapeutics has selected Idiopathic Pulmonary Fibrosis (IPF) as its lead program. Other fibrotic diseases or metabolic diseases are under evaluation.

Contacts

StarkAge Therapeutics
Institut Pasteur Lille – 1 Rue du Professeur Calmette – 59800 Lille – Tel:  +33 3 74 02 03 03

Public Relations & Medias
Dr. Thierry Mathieu, President
thierry.mathieu@StarkAgeTX.com

Investors / Analysts
Dr. Pierre-Michel Bringer, CEO
pierre-michel.bringer@StarkAgeTX.com

Academia and Scientific community
Dr. Frédérik Oger, CSO
frederik.oger@StarkAgeTX.com

References

  1. https://starkagetx.com/starkage-therapeutics-awarded-e2m-from-bpifrance-to-develop-innovative-immunotherapy-approach-targeting-senescent-cells-in-age-related-diseases/
  2. Hernandez-Gonzalez F et al., Cellular Senescence in Lung Fibrosis. Int J Mol Sci. 2021 Jun 29;22(13):7012.
  3. Kellogg DL et al., Cellular Senescence in Idiopathic Pulmonary Fibrosis. Curr Mol Biol Rep. 2021 Aug 12:1-10
  4. Baker DJ et al., Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest. 2018 Apr 2;128(4):1208-1216.
  5. Palmer AK et al.,Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. 2019;18(3):e12950.
  6. Aguayo-Mazzucato C et al., Acceleration of beta Cell Aging Determines Diabetes and Senolysis Improves Disease Outcomes. Cell Metab. 2019.
  7. Ogrodnik M et al., Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017;8:15691.
  8. OMICs : https://en.wikipedia.org/wiki/Multiomicshttps://en.wikipedia.org/wiki/Omics
  9. IPF: https://err.ersjournals.com/content/21/126/355
  10. IPF prevalence:  https://www.nhs.uk/conditions/idiopathic-pulmonary-fibrosis/
  11. IPF death rate : https://www.medscape.com/answers/301226-95979/what-is-the-mortality-rate-of-idiopathic-pulmonary-fibrosis-ipf
  12. Di Micco, R., Krizhanovsky, V., Baker, D. et al. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol 22, 75–95 (2021).
    https://www.nature.com/articles/s41580-020-00314-w
  13. Rossi, M.; Abdelmohsen, K. The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets. Cells 2021, 10, 1740.
    https://www.mdpi.com/2073-4409/10/7/1740

StarkAge Therapeutics awarded €2m from BPI France to develop innovative immunotherapy approach targeting senescent cells in age-related diseases

–  StarkAge Tx awarded €2 Million through Bpifrance’s “Deeptech Program”
–  Bpifrance’s Deeptech program aims to finance disruptive R&D programs
–  Early development of biomarker platform ExoCiseTM now secured
–  Pierre-Michel Bringer appointed Chief Executive Officer


Lille, France, January 18, 2022
– StarkAge Therapeutics, a pioneering discovery-stage biotechnology company focusing on cellular senescence related diseases, announced today it received Bpifrance Deeptech label designation for its lead program in Idiopathic Pulmonary Fibrosis (IPF).

“This exceptional achievement, under the scientific leadership of Dr. Müge Ogrunc, underscores the potential of the technology we are developing.” said Dr. Thierry Mathieu founder and President of StarkAge Therapeutics. “We are grateful for the strong and continuous support from Bpifrance since the creation of StarkAge Therapeutics”.

With this label, StarkAge Tx was awarded 2€ million in non-dilutive funding, the maximum allowed per project in this program1, across 4 years. This is a major steppingstone to advance and drive their program to success.

A further increase in capital will likely be required to fully fund their pre-clinical IPF program prior to engaging with US and European regulatory agencies.

“This will help us move our research forward significantly” added Dr. Mathieu. “IPF is the first program we are testing with ExoCiseTM, our cellular senescence biomarker platform. If successfully completed, it could lead to helping with  many other age-related diseases.”

StarkAge Therapeutics also announced that Dr. Pierre-Michel Bringer, has been appointed Chief Executive Officer. Dr. Bringer has over 35 years of Pharmaceutical Industry experience in multiple countries including the US, spanning M&A / licensing, communication, strategic planning, marketing & sales. Most recently he served 13 years as Investor Relations Officer with Novartis. Pierre-Michel holds a Doctorate of Pharmacy from Paris University

“Pierre-Michel broad industry knowledge, including expertise with investors, and his passion for science make him the strong leader we needed” said Dr. Mathieu “We are thrilled to have Pierre-Michel with us as CEO, and I am happy to hand-over the helm of StarkAge Therapeutics”.

“I feel honored and humbled to lead the next steps of StarkAge Therapeutics whose science focuses on harnessing immunotherapy against cellular senescence.” said Dr. Bringer.

About senescence

Cellular senescence is a stress-induced, durable cell-cycle arrest of previously replication-competent cells. Senescent cells can be beneficial as well as detrimental regarding host physiology and disease. Indeed, while cellular senescence can facilitate physiological processes such as tissue repair and wound healing, the actions of their secreted pro-inflammatory cytokines can promote tissue dysfunctions, especially during aging. In this context, the rate at which senescent cells accumulate within tissues increases with aging leading to age-related disorders causing diseases such as idiopathic pulmonary fibrosis2,3 (IPF) and many others4,5,6,7. Consequently, these detrimental senescent cells are considered a potential therapeutic target in age-related disorders. Nevertheless, the challenge remains to specifically target detrimental senescent cells while avoiding altering the functions of beneficial ones.

About Bpifrance Deeptech program

Bpifrance’s Deeptech program1 aims to help finance well-characterized and disruptive R&D programs.

The DeepTech label is granted to projects based on innovative technology, in particular:

  • from a research laboratory (public/private) and/or relying on a team/governance in connection with the scientific world
  • which constitute a strongly differentiating advantage compared to the competition
  • characterized by a long/complex go-to-market (development, industrialization, marketing) and therefore probably capital-intensive.

About ExoCiseTM

ExoCise is StarkAge Therapeutics’ proprietary platform designed to analyze extracellular vesicles (EVs), particularly exosomes and microvesicles, identifying robust and specific biomarkers for senescent cells in disease-setting by their specific multi-OMICs8 characterization.

EVs are secreted by virtually all cell types in the body and released in body fluids, particularly blood. EVs contain various molecules such as RNA, proteins, enzymes, cytokines etc.  Some of these molecules are specific to the tissue they originate from, and even specific to certain cells within that tissue (biomarkers). EVs secreted from diseased or senescent cells to the blood could be used to detect and diagnose such conditions with a simple blood draw.

By applying ExoCise to patients with age-related diseases involving senescent cell accumulation, StarkAge Therapeutics expects to design safe and targeted immunotherapy solutions, setting StarkAge Therapeutics apart from competitors’ approaches with senolytic drugs which lacked safety and selectivity.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a severe and debilitating disease with limited-or-no therapeutic options, in which the lungs become fibrotic and scarred9. It is a progressive illness where breathing becomes increasingly difficult over time until patients die from IPF.  There is currently no treatment that can stop the evolution of the disease, or even reverse the scarring of the lungs.

IPF prevalence10 is estimated between 14 and 27.9 cases per 100,000 habitants in the US, in Europe 1.25 to 23.4 cases per 100,000 habitants in Europe.

With regard to IPF life expectancy11, the estimated mean survival is 2-5 years from the time of diagnosis. Estimated mortality rates are 64.3 deaths per million in men and 58.4 deaths per million in women.

About StarkAge Therapeutics

StarkAge Therapeutics (SATX) is a pioneering privately held discovery-stage biotechnology company based in Lille, France. It was founded in 2018 by Dr. Thierry Mathieu, with scientific support from Dr. Müge Ogrunc, based on the idea that eliminating disease-specific senescent cells using immunotherapy could deliver significant therapeutic benefits to patients.

Its ambition is to delay or halt disease progression and improve the quality of life of patients with age-related diseases.

Increasing evidence in literature confirms senescent cell accumulation as a hallmark in various aged-related diseases such as idiopathic pulmonary fibrosis2,3, neurodegenerative diseases4, metabolic dysfunction5,6 or hepatic steatosis7. Recent scientific reviews12,13 identified potential targets and set the foundations for testing applications in human.

StarkAge Therapeutics’ unique expertise originates from its proprietary biomarker discovery platform, ExoCiseTM, which enables the characterization of senescent cell biomarkers from patient derived extracellular vesicles and their specific validation for each disease.

StarkAge Therapeutics has selected Idiopathic Pulmonary Fibrosis (IPF) as its lead program. Other fibrotic diseases or metabolic diseases are under evaluation.

Contacts

StarkAge Therapeutics
Institut Pasteur Lille – 1 Rue du Professeur Calmette – 59800 Lille – Tel:  +33 3 74 02 03 03

Public Relations & Medias
Dr. Thierry Mathieu, President
thierry.mathieu@StarkAgeTX.com

Investors / Analysts
Dr. Pierre-Michel Bringer, CEO
pierre-michel.bringer@StarkAgeTX.com

References

  1. https://www.Bpifrance.fr/catalogue-offres/soutien-a-linnovation/aide-au-developpement-deeptech (last read January 10, 2022)
  2. Hernandez-Gonzalez F et al., Cellular Senescence in Lung Fibrosis. Int J Mol Sci. 2021 Jun 29;22(13):7012.
  3. Kellogg DL et al., Cellular Senescence in Idiopathic Pulmonary Fibrosis. Curr Mol Biol Rep. 2021 Aug 12:1-10
  4. Baker DJ et al., Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest. 2018 Apr 2;128(4):1208-1216.
  5. Palmer AK et al.,Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. 2019;18(3):e12950.
  6. Aguayo-Mazzucato C et al., Acceleration of beta Cell Aging Determines Diabetes and Senolysis Improves Disease Outcomes. Cell Metab. 2019.
  7. Ogrodnik M et al., Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017;8:15691.
  8. OMICs : https://en.wikipedia.org/wiki/Multiomicshttps://en.wikipedia.org/wiki/Omics
  9. IPF: https://err.ersjournals.com/content/21/126/355
  10. IPF prevalence:  https://www.nhs.uk/conditions/idiopathic-pulmonary-fibrosis/
  11. IPF death rate : https://www.medscape.com/answers/301226-95979/what-is-the-mortality-rate-of-idiopathic-pulmonary-fibrosis-ipf
  12. Di Micco, R., Krizhanovsky, V., Baker, D. et al. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol 22, 75–95 (2021).
    https://www.nature.com/articles/s41580-020-00314-w
  13. Rossi, M.; Abdelmohsen, K. The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets. Cells 2021, 10, 1740.
    https://www.mdpi.com/2073-4409/10/7/1740